Sorry, you need to enable JavaScript to visit this website.


Advancing Knowledge and Public Health

Pfizer Rare Disease is built on innovation. We pride ourselves in stretching the limits of traditional partnership and collaborative research models by working in new and meaningful ways with innovators in government, academia, advocacy, and across the industry. We believe a networked R&D model that leverages the strengths across all sectors will drive the next generation of breakthrough therapies.

Our ongoing rare disease collaborative research in gene therapy is one example of our cutting-edge approach to developing new therapies. We are continuing to identify and engage new partners to advance our rAAV-based platform and capabilities, leading to several pre-clinical and clinical programs.

Through trusted rare disease partnerships and collaborations—and a shared urgency and relentless passion to make a difference in patients’ lives—Pfizer Rare Disease is supporting programs and initiatives that we believe can benefit the public, advance medical care, and improve patient outcomes.

Rare Disease Grants & Contributions

Here you will find some general information on grants, funding, and other opportunities that are now available to help improve the lives of patients with rare diseases.

Select All | Select None


Healthcare Charitable Contributions

Pfizer offers funding to qualified 501(c)(3) organizations for certain healthcare-related programs/activities for patients. This type of support is limited to the following: 1) patient education, including health screening; 2) patient advocacy for disease awareness, and 3) patient access to care (e.g., transportation costs).

Lobbying and Political Contributions

In the highly regulated and competitive pharmaceutical industry, it is crucial to our stakeholders that we engage in public policy issues that may affect our ability to meet patient needs and enhance shareholder value. This site contains information around corporate and employee Political Action Committee contributions.

Research and Education


Pfizer offers funding for independent medical education activities or initiatives which serve to maintain, develop, or increase the knowledge, skills, and/or professional performance of a healthcare professional (e.g. continuing medical education, continuing health education, continuing education.) These activities or initiatives may or may not be accredited.


Pfizer is able to support investigators in conducting their own research by providing funding and/or drug/pure compound for pre-clinical, early clinical, and late clinical research through the Investigator Sponsored Research program.

Rare Disease Partnerships

We believe that together we gain knowledge faster and increase momentum across the drug development continuum. From discovery, to clinical, to commercial stages, we are looking for partnership opportunities that can to help us with our goal of delivering transformative medicines to patients most in need.

Pfizer Rare Disease partnerships focus on a broad range of therapeutic areas and novel platforms including:

Therapeutic Areas
  • Hematology
  • Neuromuscular/Neurology/Amyloidosis
  • Endocrine/Inborn Errors of Metabolism
  • Cardiomyopathies
  • Nephrology
  • Cardiology
Novel Platforms
  • Gene Therapy

Partnering on Discovery Through Early-Stage Clinical Development

To inquire about partnership opportunities at early stages of development (generally prior to clinical proof-of-concept) in Rare Disease, please contact the Pfizer External Research & Development Innovation (ERDI) group within Worldwide Research & Development (WRD).

Further information on WRD Rare Disease partnering >>

Partnering on Late-Stage Clinical Development Through Commercialization

To inquire about partnership opportunities at late-stages of development (generally after clinical proof-of-concept), please contact the Pfizer Worldwide Business Development group within Biopharmaceuticals.

Further information on Biopharmaceuticals Group partnering >>


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent quality improvement initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Visit Quality Improvement